Bioventix delivered a strong set of interims, with revenues up 21%. Given the 9% decline in operating expenses, this resulted in a 31% increase in adjusted EBITDA, with adjusted pre-tax profit also rising 31% to £4.4m (52% of full-year forecasts) and adjusted EPS up 29% to 69.4p. An interim dividend of 36p was declared (+20%) with net cash at period end of £5.5m. Growth was driven by both Vitamin D antibody sales/royalties (+c.25%), its portfolio of other antibodies (+c.12%) and a
30 Mar 2020
Bioventix - Interims – pre-COVID growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bioventix - Interims – pre-COVID growth
Bioventix Plc (BVXP:LON) | 4,600 0 0.0% | Mkt Cap: 240.1m
- Published:
30 Mar 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
12
Bioventix delivered a strong set of interims, with revenues up 21%. Given the 9% decline in operating expenses, this resulted in a 31% increase in adjusted EBITDA, with adjusted pre-tax profit also rising 31% to £4.4m (52% of full-year forecasts) and adjusted EPS up 29% to 69.4p. An interim dividend of 36p was declared (+20%) with net cash at period end of £5.5m. Growth was driven by both Vitamin D antibody sales/royalties (+c.25%), its portfolio of other antibodies (+c.12%) and a